Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate or enzalutamide

Abstract Authors: Megan Ann McNamara, Daniel J. George, Krishnan Ramaswamy, Stanislav Lechpammer, Jack Mardekian, Neil M. Schultz, Li Wang, Onur Baser, Ahong Huang, Stephen J. Freedland Background: Prostate cancer (PC) is the most common malignancy among US men and...